Isis Pharmaceuticals Inc., of Carlsbad, Calif., elected Spencer Berthelsen to its board.
ISTA Pharmaceuticals Inc., of Irvine, Calif., added Jeffrey Edwards to its board.
Lehman Bros., of New York, added Craig Parker as head of its biotechnology equity research coverage in the U.S.
Libraria Inc., of San Jose, Calif., appointed Bob Reed chief business officer.
Lynx Therapeutics Inc., of Hayward, Calif., added Thomas Vasicek as vice president, business development. Richard Woychik, Lynx's chief scientific officer, was named the new director of The Jackson Laboratory in Bar Harbor, Maine, but he will be added to Lynx's board to remain in contact with the company.
Medarex Inc., of Princeton, N.J., added Israel Lowy as director, infectious diseases.
Morphotek Inc., of Exton, Pa., appointed Rodney Dausch vice president and chief financial officer.
North Carolina Biotechnology Center, of Research Triangle Park, N.C., appointed Leslie Alexandre president and CEO, effective Aug. 1.
Orchid BioSciences Inc., of Princeton, N.J., appointed Nicole Williams to its board.
Protalex Inc., of Albuquerque, N.M., added Thomas Stagnaro to its board.
PsychoGenics Inc., of Hawthorne, N.Y., added Mark Hofer as general counsel.
Ribozyme Pharmaceuticals Inc., of Boulder, Colo., appointed Barry Polisky vice president of research, and promoted Larry Kahn to vice president of business development and Bharat Chowrira to vice president, legal affairs, licensing and patent counsel.
Rib-X Pharmaceuticals Inc., of New Haven, Conn., appointed Robert Conerly chief financial officer and vice president of finance.
Sunesis Pharmaceuticals Inc., of South San Francisco, appointed Brian Metcalf to its scientific advisory board.
Synaptic Pharmaceutical Corp., of Paramus, N.J., promoted Thomas Blackburn to vice president of drug discovery operations.
Third Wave Technologies Inc., of Madison, Wis., added Sam Eletr to its board.
Viragen Inc., of Plantation, Fla., appointed Douglas Lind senior adviser for corporate strategy.
Xcyte Therapies Inc., of Seattle, appointed Lewis Chapman chief business officer.
Xmark Funds, of New York, added Richard Burgoon as a principal.